PMID: 11604551Oct 18, 2001Paper

Multicenter phase II study of gemcitabine in previously untreated patients with advanced epithelial ovarian cancer

Anti-cancer Drugs
C R UnderhillC Williams

Abstract

Gemcitabine has activity in advanced ovarian cancer, with responses in platinum-resistant disease. This study assessed the activity of gemcitabine in previously untreated patients with advanced epithelial ovarian cancer. All patients had histologically verified invasive epithelial ovarian cancer, International Federation of Gynecology and Obstetrics (FIGO) stage III/IV disease and no prior chemotherapy. Patients received gemcitabine 1250 mg/m(2) on days 1, 8 and 15 of a 28-day cycle. Radiological response was assessed after two cycles. Between December 1992 and October 1995, 35 patients were enrolled. Of 33 evaluable patients, there was one complete response and five partial responses, for an overall response rate of 18% (95% confidence interval 7-36%). Forty-two percent of patients had a greater than 50% decrease in their CA-125 levels. Of the 25 patients who received platinum-based chemotherapy following treatment with gemcitabine, 12 achieved an overall response rate of 48%. Toxicity was mild, with two episodes of WHO grade 4 neutropenia (not associated with fever) and two episodes of grade 4 thrombocytopenia (not associated with bleeding). Gemcitabine has single-agent activity for poor-prognosis patients with advanced ovari...Continue Reading

References

Nov 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A I EinzigG L Goldberg
Jan 1, 1984·Journal of Cancer Research and Clinical Oncology·R M Canetta, S K Carter
Oct 19, 1994·Journal of the National Cancer Institute·B LundJ P Neijt
Aug 1, 1995·Australian and New Zealand Journal of Medicine·K A PhillipsJ Bishop
Jan 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·L CrinòM Tonato
Feb 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R P AbrattD J Hacking
Jan 1, 1994·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·K.E. WilliamsA.J. McCartney

❮ Previous
Next ❯

Citations

Aug 12, 2004·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·P KornblithD Burholt
Dec 14, 2005·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·R T PensonUNKNOWN Gynecologic Oncology Research Program at Dana Farber/Partners CancerCare
May 1, 2007·Women's Health·Fadi Abushahin, Peter G Rose
Nov 4, 2006·BJOG : an International Journal of Obstetrics and Gynaecology·S K TayT Y Tan
Sep 24, 2004·International Journal of Cancer. Journal International Du Cancer·Xavier FarréMarçal Pastor-Anglada

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.